Puissance Capital
2
28M
2
1
2
- Areas of investment
Summary
The usual cause for the fund is to invest in rounds with 4 partakers. Despite the Puissance Capital, startups are often financed by Xeraya Capital, OrbiMed, Kearny Venture Partners. The meaningful sponsors for the fund in investment in the same round are OrbiMed, Kearny Venture Partners, Acuta Capital Partners.
The usual things for fund are deals in the range of 10 - 50 millions dollars. The increased amount of exits for fund were in 2015. The top activity for fund was in 2017. The fund is constantly included in less than 2 deals per year.
Moreover, a startup needs to be at the age of 11-15 years to get the investment from the fund. Among the most popular fund investment industries, there are Health Care, Biotechnology. Among the most popular portfolio startups of the fund, we may highlight ViewRay.
Investments analytics
Analytics
- Total investments
- 2
- Lead investments
- 1
- Exits
- 2
- Investments by industry
- Biotechnology (2)
- Medical Device (1)
- Therapeutic Devices (1)
- Manufacturing (1)
- Health Care (1) Show 2 more
- Investments by region
-
- United States (2)
- Peak activity year
- 2017
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 14
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.